KIORA PHARMACEUTICALS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
KIORA PHARMACEUTICALS, INC. (KPRX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $265.86 thousand as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-25
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $265.86K.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $871.70K.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $784.37K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $782.36K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $265.86K 10-K · filed 2026-03-25 |
| 2024-12-31 | $871.70K 10-K · filed 2026-03-25 |
| 2023-12-31 | $784.37K 10-K · filed 2025-03-25 |
| 2022-12-31 | $782.36K 10-K · filed 2024-03-25 |
| 2021-12-31 | $835.43K 10-K · filed 2023-03-23 |
| 2020-12-31 | $781.25K 10-K/A · filed 2022-07-07 |
| 2019-12-31 | $814.44K 10-K · filed 2021-03-25 |
| 2018-12-31 | $639.73K 10-K · filed 2020-03-04 |
| 2017-12-31 | $552.10K 10-K · filed 2019-03-01 |
| 2016-12-31 | $323.83K 10-K · filed 2018-03-02 |
| 2015-12-31 | $164.29K 10-K · filed 2017-02-23 |
| 2014-12-31 | $100.71K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |